VectorY Therapeutics Expands ALS Trial for Antibody Therapy Before Efficacy Results

Scaling Up to Strengthen Early Signals

VectorY Therapeutics has tripled the size of its Phase 1/2 PIONEER-ALS clinical trial, increasing enrollment from 12 to 36 participants to evaluate VTx-002, an investigational antibody targeting TDP-43 pathology in amyotrophic lateral sclerosis. The expansion occurred prior to the availability of any efficacy data from the ongoing study, which is being conducted at multiple clinical sites across the United States. The decision reflects growing confidence in the therapy’s safety profile and mechanistic rationale based on preclinical evidence linking TDP-43 aggregation to neurodegeneration in ALS. By scaling up the trial now, VectorY aims to gather more robust preliminary signals on biological activity and tolerability while maintaining the study’s adaptive design framework.

The original PIONEER-ALS study was designed as a small-scale safety and pharmacodynamic trial to assess VTx-002’s engagement with extracellular TDP-43 and its potential to reduce neuroinflammatory markers. Tripling the cohort size allows for better statistical power in exploratory endpoints, including changes in neurofilament light chain levels and microglial activation observed via imaging. According to VectorY, the expansion was informed by favorable tolerability data from the first cohort and strong target engagement observed in biomarker analyses. The company emphasized that increasing participant numbers does not alter the trial’s primary objectives but enhances the ability to detect meaningful biological effects earlier in development.

How Does Targeting TDP-43 Differ From Other ALS Approaches?

Unlike gene-silencing strategies aimed at SOD1 or C9orf72 mutations, VTx-002 focuses on the pathological form of TDP-43, a protein implicated in the vast majority of ALS cases regardless of genetic background. By neutralizing extracellular TDP-43 aggregates, the therapy seeks to interrupt a proposed cycle of neurotoxicity and glial activation that drives disease progression. This approach complements intracellular strategies by targeting a shared downstream mechanism. VectorY notes that preclinical models showed reduced microglial reactivity and improved motor function following VTx-002 administration, supporting the rationale for human testing despite the absence of clinical efficacy data at this stage.

Why did VectorY expand the trial before seeing efficacy results? The expansion was based on promising safety and biomarker data from the initial cohort, allowing the company to gather more meaningful exploratory signals without waiting for full efficacy outcomes.

Frequently Asked Questions

Is VTx-002 intended only for familial ALS cases? No, the therapy targets TDP-43 pathology, which is present in over 90% of ALS cases, making it potentially applicable to both sporadic and familial forms of the disease.

What are the next steps after the PIONEER-ALS trial? VectorY plans to use data from the expanded trial to inform dose selection and trial design for a potential Phase 2b study focused on clinical endpoints such as functional decline and survival.